Epigenetic regulation of ADME-related genes: Focus on drug metabolism and transport

Drug Metabolism and Disposition

Volumn 41, Issue 10, 2013, Pages 1721-1724

  Zhong, Xiao Bo ^a   Leeder, J Steven ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CYTOCHROME P450 1A2; CYTOCHROME P450 2B9; CYTOCHROME P450 2C11; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DNA; GLUCURONOSYLTRANSFERASE 1A1; HEPATOCYTE NUCLEAR FACTOR 1; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HISTONE; INSULIN; MESSENGER RNA; ORGANIC ANION TRANSPORTER; PREGNANE X RECEPTOR; RIFAMPICIN; UNTRANSLATED RNA; XENOBIOTIC AGENT;

ARTICLE; CHROMATIN STRUCTURE; DNA METHYLATION; DNA MODIFICATION; DNA PACKAGING; DNA SEQUENCE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HERITABILITY; HISTONE MODIFICATION; HUMAN; NONHUMAN; ORGANOGENESIS; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; TISSUE SPECIFICITY;

ABSORPTION; BIOLOGICAL TRANSPORT; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84884683951     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053942     Document Type: Article

References (40)

1. Baylin SB and Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11:726-734.
2. Benson E and Skaar T (2013) Analysis of miRNA stability in whole blood for use in drug metabolism biomarker studies. Drug Metab Dispos 41:1778-1781.
3. Bird A (2007) Perceptions of epigenetics. Nature 447:396-398.
4. Chai X, Zeng S, and Xie W (2013) Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin Drug Metab Toxicol 9:253-266.
5. Choudhuri S, Cui Y, and Klaassen CD (2010) Molecular targets of epigenetic regulation and effectors of environmental influences. Toxicol Appl Pharmacol 245:378-393.
6. Descombes P and Schibler U (1991) A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 67:569-579. (Pubitemid 121001471)
7. Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250-267.
8. Imai S, Kikuchi R, Kusuhara H, and Sugiyama Y (2013) DNA methylation and histone modification profiles of mouse organic anion transporting polypeptides. Drug Metab Dispos 41:72-78.
9. Ingelman-Sundberg M, Zhong X, Hankinson O, Beedanagari S, Yu A-M, Peng L, and Osawa Y (2013) Epigenetic Mechanisms in Drug Metabolism and Transport. Drug Metab Dispos 41:1725-1731.
10. Jin B, Park DW, Nam KW, Oh GT, Lee YS, and Ryu DY (2004) CpG methylation of the mouse CYP1A2 promoter. Toxicol Lett 152:11-18. (Pubitemid 39030782)
11. Kacevska M, Ivanov M, and Ingelman-Sundberg M (2011) Perspectives on epigenetics and its relevance to adverse drug reactions. Clin Pharmacol Ther 89:902-907.
12. Kacevska M, Ivanov M, and Ingelman-Sundberg M (2012a) Epigenetic-dependent regulation of drug transport and metabolism: an update. Pharmacogenomics 13:1373-1385.
13. Kacevska M, Ivanov M, Wyss A, Kasela S, Milani L, Rane A, and Ingelman-Sundberg M (2012b) DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie 94:2338-2344.
14. Kikuchi R, Yagi S, Kusuhara H, Imai S, Sugiyama Y, and Shiota K (2010) Genome-wide analysis of epigenetic signatures for kidney-specific transporters. Kidney Int 78:569-577.
15. Lacroix D, Sonnier M, Moncion A, Cheron G, and Cresteil T (1997) Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625-634. (Pubitemid 27308642)
16. Leeder J and Zhong X (2013) Epigenetic Regulation of ADME-Related Genes: Focus on Drug Metabolism and Transport. Drug Metab Dispos 41:1721-1724.
17. Li Y, Cui Y, Hart SN, Klaassen CD, and Zhong XB (2009) Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. Mol Pharmacol 75:1171-1179.
18. Ling G, Wei Y, and Ding X (2007) Transcriptional regulation of human CYP2A13 expression in the respiratory tract by CCAAT/enhancer binding protein and epigenetic modulation. Mol Pharmacol 71:807-816. (Pubitemid 46294092)
19. Mill J and Heijmans BT (2013) From promises to practical strategies in epigenetic epidemiology. Nat Rev Genet 14:585-594.
20. Oda S, Fukami T, Yokoi T, and Nakajima M (2013) Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney. Drug Metab Dispos 41:1738-1743.
21. Pan YZ, Gao W, and Yu AM (2009) MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37:2112-2117.
22. Pan Y-Z, Zhou A, Hu Z, and Yu A-M (2013) Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 41:1744-1751.
23. Pandey AV and Flück CE (2013) NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol Ther 138:229-254.
24. Ramamoorthy A, Liu Y, Philips S, Desta Z, Lin H, Goswami C, Gaedigk A, Li L, Flockhart D, and Skaar T (2013) Drug Metab Dispos 41:1763-1768.
25. Reik W (2007) Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447:425-432.
26. Rieger JK, Klein K, Winter S, and Zanger UM (2013) Expression variability of ADME-related microRNAs in human liver: influence of non-genetic factors and association with gene expression. Drug Metab Dispos 41:1752-1762.
27. Schuetz JD, Beach DL, and Guzelian PS (1994) Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11-20.
28. Shiota K (2004) DNA methylation profiles of CpG islands for cellular differentiation and development in mammals. Cytogenet Genome Res 105:325-334.
29. Shukla U, Tumma N, Gratsch T, Dombkowski A, and R Novak (2013) Insulin-Mediated Regulation of the miR132/212 Cluster and miR 122/181a Expression Through PI3-K, Akt, mTOR Signaling in Primary Cultured Rat Hepatocytes. Drug Metab Dispos 41:1769-1777.
30. Ström A, Eguchi H, Mode A, Legraverend C, Tollet P, Strömstedt PE, and Gustafsson JA (1994) Characterization of the proximal promoter and two silencer elements in the CYP2C11 gene expressed in rat liver. DNA Cell Biol 13:805-819.
31. Umeno M, Song BJ, Kozak C, Gelboin HV, and Gonzalez FJ (1988) The rat P450IIE1 gene: complete intron and exon sequence, chromosome mapping, and correlation of developmental expression with specific 5′ cytosine demethylation. J Biol Chem 263:4956-4962.
32. Vieira I, Pasanen M, Raunio H, and Cresteil T (1998) Expression of CYP2E1 in human lung and kidney during development and in full-term placenta: a differential methylation of the gene is involved in the regulation process. Pharmacol Toxicol 83:183-187. (Pubitemid 28512134)
33. Vieira I, Sonnier M, and Cresteil T (1996) Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 238:476-483.
34. Vyhlidal CA, Gaedigk R, and Leeder JS (2006) Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos 34:131-137. (Pubitemid 43042654)
35. Wang Z, Yao H, Lin S, Zhu X, Shen Z, Lu G, Poon WS, Xie D, Lin MC, and Kung HF (2013) Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett 331:1-10.
36. Waxman DJ and Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76:215-228.
37. Yokoi T and Nakajima M (2013) microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 53:377-400.
38. Yokomori N, Kobayashi R, Moore R, Sueyoshi T, and Negishi M (1995) A DNA methylation site in the male-specific P450 (Cyp 2d-9) promoter and binding of the heteromeric transcription factor GABP. Mol Cell Biol 15:5355-5362.
39. Xie X, Miao L, Yao J, Feng C, Li C, Gao M, Liu M, Gong L, Wang Y, Qi X, et al. (2013) Role of multiple microRNAs in the sexually dimorphic expression of Cyp2b9 in mouse liver. Drug Metab Dispos 41:1732-1737.
40. Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141.